Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Pulmonology

Mapping Your Disease: Spirometry and GOLD Staging

At a Glance

COPD is usually confirmed when post-bronchodilator spirometry shows an FEV1/FVC ratio below 0.70. FEV1 percent predicted sets the GOLD airflow grade, while symptom scores and recent exacerbations determine the GOLD ABE group and help guide treatment.

A diagnosis of COPD is not a “guess” based on a cough or a history of smoking. It is a precise determination made using specific breathing tests and a history of how you feel. To ensure you receive the right treatment, doctors use a global standard called the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines to “grade” and “group” your condition [1][2].

The Diagnostic Standard: Spirometry

The standard way to formally diagnose airflow obstruction is through spirometry, a test where you blow into a tube to measure how much air you can hold and how fast you can blow it out [3].

For a COPD diagnosis, this test must be “post-bronchodilator.” This means you perform the test, take a puff of a quick-acting inhaler to open your airways, and then repeat the test after about 15–20 minutes [1].

  • The Ratio: Doctors look at the FEV1/FVC ratio (the amount of air you can force out in one second compared to the total air you can exhale).
  • The Threshold: A diagnosis is typically confirmed if your post-bronchodilator ratio is less than 0.70 [1][3].
  • Borderline Results: The fixed 0.70 ratio can sometimes overdiagnose obstruction in older adults and underdiagnose it in younger adults. If your ratio is borderline, your doctor may suggest repeating the test and interpreting it within your clinical context, sometimes utilizing a “lower limit of normal” (LLN) or z-scores [3][4].

Understanding Your GOLD Grade (1–4)

Once the diagnosis is confirmed, your doctor will assign a spirometric GOLD Grade based on your FEV1% predicted. This number compares your lung power to a healthy person of your same age, height, and sex [5][6].

It is critical to know that this grade measures the severity of your airflow obstruction, not your overall disease severity, symptom burden, exacerbation risk, or prognosis. A patient can have “Mild” obstruction but feel highly restricted, or “Severe” obstruction and feel relatively active.

  • Grade 1: Mild airflow obstruction (80% or higher) [5].
  • Grade 2: Moderate airflow obstruction (50% to 79%) [6].
  • Grade 3: Severe airflow obstruction (30% to 49%) [5].
  • Grade 4: Very Severe airflow obstruction (Less than 30%) [6].

The ABE Classification: Symptoms and Flare-ups

While the Grade (1–4) tells us about your lung “plumbing,” the GOLD ABE Assessment (updated in the 2026 GOLD report) tells us how the disease actually affects your life. This classification helps your doctor decide which medications to start [7][8].

Step 1: Measuring Your Symptoms

Doctors use two main tools to measure your daily “symptom burden”:

  1. mMRC (Modified Medical Research Council): A simple 0–4 scale focused only on breathlessness. A score of 2 or higher (stopping for breath when walking at your own pace) is considered a high symptom burden [9].
  2. CAT (COPD Assessment Test): A more detailed 8-question survey covering cough, mucus, and sleep. A score of 10 or higher is considered a high symptom burden [9][10].

Step 2: Sorting into Groups

Under the 2026 GOLD criteria update, the groups are mutually exclusive:

  • Group A: Low symptoms (mMRC 0–1 or CAT < 10) AND zero moderate or severe exacerbations in the last year [11].
  • Group B: High symptoms (mMRC ≥ 2 or CAT ≥ 10) AND zero moderate or severe exacerbations in the last year [11].
  • Group E (Exacerbation): This category incorporates the 2026 update. You are in Group E if you have had at least one moderate or severe (hospitalized) flare-up in the last 12 months, regardless of your daily symptoms [7][8][12].

Checking for Genetic Causes (Alpha-1)

In some cases, COPD isn’t caused by smoking or pollution alone, but by a genetic condition called Alpha-1 Antitrypsin Deficiency (AATD) [13].

Current guidelines recommend that every adult diagnosed with COPD should be tested for AATD at least once [13][14]. This is especially critical if:

  • You were diagnosed at an unusually young age (often under 45) [15][16].
  • You have never smoked or had very little smoke exposure [16].
  • Your emphysema is mostly in the lower parts of your lungs [17].

Testing usually starts with a simple blood test to measure the level of the Alpha-1 protein in your system [15][18]. Identifying this deficiency can change your treatment plan significantly, as specialized “augmentation therapy” may be available [19].

Common questions in this guide

How does spirometry confirm COPD?
Doctors usually confirm COPD when a post-bronchodilator FEV1/FVC ratio is below 0.70, meaning airflow remains obstructed after an inhaler opens the airways. A borderline result may need repeat testing or comparison with the lower limit of normal and age-related reference values.
What do GOLD Grades 1 through 4 mean on my spirometry report?
The grades are based on FEV1 percent predicted: Grade 1 is 80% or higher, Grade 2 is 50% to 79%, Grade 3 is 30% to 49%, and Grade 4 is below 30%. The grade describes airflow obstruction only; it does not by itself measure symptom burden, flare-up risk, or prognosis.
How are COPD GOLD Groups A, B, and E assigned?
Group A means low symptoms, such as an mMRC score of 0 to 1 or a CAT score below 10, and no moderate or severe exacerbations in the last year. Group B means high symptoms with no such exacerbations, while Group E includes anyone with at least one moderate or severe exacerbation in the previous 12 months, regardless of daily symptom level.
What do my CAT and mMRC scores mean?
The mMRC scale measures breathlessness from 0 to 4, and a score of 2 or higher indicates a high symptom burden. The CAT is an eight-question survey about COPD effects such as cough, mucus, and sleep; a score of 10 or higher indicates high symptom burden.
Should everyone with COPD be tested for Alpha-1 antitrypsin deficiency?
Current guidelines recommend that every adult diagnosed with COPD be tested at least once. Testing is especially important after a diagnosis at a young age, with little or no smoking exposure, lower-lung emphysema, or a family history of early emphysema or Alpha-1 deficiency. A blood test measures the protein level, and finding a deficiency may make augmentation therapy an option.
Does a mild COPD GOLD grade mean my disease is mild overall?
No. The spirometric grade describes how limited airflow is on the breathing test, while symptoms, exacerbations, and the rest of your clinical context show how COPD affects you. These factors also help guide treatment and cannot be replaced by the FEV1 grade alone.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my post-bronchodilator FEV1/FVC ratio, and given my age, did you compare it to the 'lower limit of normal' (LLN)?
  2. 2.My FEV1 is [percentage]—I understand this tells us my spirometric Grade (1-4), but how does my overall clinical condition look?
  3. 3.Am I in GOLD Group A, B, or E? Specifically, did my exacerbations last year meet the criteria for Group E?
  4. 4.Since my CAT score was [number], what specific symptoms are driving that score, and how will our treatment plan address them?
  5. 5.Can we order a serum Alpha-1 Antitrypsin test to rule out a genetic cause, especially since I was diagnosed at a younger age?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    The effect of a post-bronchodilator FEV1/FVC < 0.7 on COPD diagnosis and treatment: a regression discontinuity design.

    Moffett AT, Halpern SD, Weissman GE

    Respiratory research 2025; (26(1)):122 doi:10.1186/s12931-025-03198-6.

    PMID: 40170167
  2. 2

    Outpatient Chronic Obstructive Pulmonary Disease Management: Going for the GOLD.

    Bellinger CR, Peters SP

    The journal of allergy and clinical immunology. In practice 2015; (3(4)):471-8; quiz 479-80.

    PMID: 26164571
  3. 3

    Under- and over-diagnosis of COPD: a global perspective.

    Ho T, Cusack RP, Chaudhary N, et al.

    Breathe (Sheffield, England) 2019; (15(1)):24-35 doi:10.1183/20734735.0346-2018.

    PMID: 30838057
  4. 4

    Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohort.

    van Dijk W, Tan W, Li P, et al.

    Annals of family medicine 2015; (13(1)):41-8 doi:10.1370/afm.1714.

    PMID: 25583891
  5. 5

    COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV1 - a post-hoc analysis of pooled data.

    Chai CS, Ng DL, Bt Mos S, et al.

    BMC pulmonary medicine 2023; (23(1)):150 doi:10.1186/s12890-023-02436-1.

    PMID: 37118725
  6. 6

    The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset.

    Calverley PMA, Papi A, Page C, et al.

    International journal of chronic obstructive pulmonary disease 2022; (17()):1909-1920 doi:10.2147/COPD.S369804.

    PMID: 36034589
  7. 7

    The high-risk B-to-E transitional phenotype: a prospective multi-centre validation of patient reclassification under the updated GOLD 2026 criteria.

    Zhang B, Zeng J, Zeng H, et al.

    Journal of global health 2026; (16()):04205 doi:10.7189/jogh.16.04205.

    PMID: 42464959
  8. 8

    GOLD 2026 COPD ABE assessment tool to identify individuals at high risk in a UK multicentre COPD cohort (ERICA).

    Adesoye G, Watson A, Zhao T, et al.

    BMJ open respiratory research 2026; (13(1)) doi:10.1136/bmjresp-2025-004075.

    PMID: 42350075
  9. 9

    The relationship between swallowing function and clinical parameters in patients with chronic obstructive pulmonary disease.

    Demir Yazici S, Söyler AK, Uçar HA

    BMC pulmonary medicine 2026; (26(1)).

    PMID: 42426728
  10. 10

    Features of COPD patients by comparing CAT with mMRC: a retrospective, cross-sectional study.

    Huang WC, Wu MF, Chen HC, et al.

    NPJ primary care respiratory medicine 2015; (25()):15063 doi:10.1038/npjpcrm.2015.63.

    PMID: 26538368
  11. 11

    Exacerbation Risk and Mortality in Global Initiative for Chronic Obstructive Lung Disease Group A and B Patients with and without Exacerbation History.

    Vanfleteren LEGW, Lindberg A, Zhou C, et al.

    American journal of respiratory and critical care medicine 2023; (208(2)):163-175 doi:10.1164/rccm.202209-1774OC.

    PMID: 37040482
  12. 12

    GOLD 2026: Transforming COPD Management with Early Intervention, Multi-dimensional Assessment, and Personalized Care.

    Cazzola M, Bajpai J, Calzetta L, et al.

    Drugs 2026; (86(5)):581-597 doi:10.1007/s40265-026-02303-3.

    PMID: 41806208
  13. 13

    The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.

    Sandhaus RA, Turino G, Brantly ML, et al.

    Chronic obstructive pulmonary diseases (Miami, Fla.) 2016; (3(3)):668-682 doi:10.15326/jcopdf.3.3.2015.0182.

    PMID: 28848891
  14. 14

    Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups.

    Foreman MG, Wilson C, DeMeo DL, et al.

    Annals of the American Thoracic Society 2017; (14(8)):1280-1287 doi:10.1513/AnnalsATS.201611-838OC.

    PMID: 28380308
  15. 15

    State-of-the-art testing for alpha-1 antitrypsin deficiency.

    Kueppers F, Sanders C

    Allergy and asthma proceedings 2017; (38(2)):108-114 doi:10.2500/aap.2017.38.4031.

    PMID: 28120746
  16. 16

    Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease.

    Fouka E, Vrouvaki A, Moustaka Christodoulou M, et al.

    Medicina (Kaunas, Lithuania) 2026; (62(4)) doi:10.3390/medicina62040639.

    PMID: 42075511
  17. 17

    Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency in an Elderly Patient.

    Ragnoli B, Pochetti P, Veselagu X, Malerba M

    Diagnostics (Basel, Switzerland) 2026; (16(9)) doi:10.3390/diagnostics16091329.

    PMID: 42122032
  18. 18

    Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis.

    Greulich T, Vogelmeier CF

    Therapeutic advances in respiratory disease 2016; (10(1)):72-84 doi:10.1177/1753465815602162.

    PMID: 26341117
  19. 19

    The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency: The Association Between Diagnostic Delay and Worsened Clinical Status.

    Tejwani V, Nowacki AS, Fye E, et al.

    Respiratory care 2019; (64(8)):915-922 doi:10.4187/respcare.06555.

    PMID: 30914495

This page is for informational purposes only and does not constitute medical advice. A clinician should interpret your spirometry, symptoms, exacerbation history, and Alpha-1 testing for your individual care.

Get notified when new evidence is published on chronic obstructive pulmonary disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.